Content Conference Coverage Conferences HIV Drug Therapy 2016
HIV Glasgow: 4-Days-On-3-Days-Off HIV Treatment Controls Viral Load in Pilot Study
- Details
- Category: HIV Treatment
- Created on Monday, 14 November 2016 00:00
An experimental "4 days on, 3 days off" antiretroviral regimen kept viral load fully suppressed in 96% of people for 48 weeks in a French study presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) last week. The study recruited people whose viral load had been fully suppressed on standard treatment for a median of 4 years, not people who had started therapy recently.
HIV Glasgow: 2-Drug HIV Therapy Just as Effective as Standard 3-Drug Therapy
- Details
- Category: HIV Treatment
- Created on Tuesday, 25 October 2016 00:00
Simplification of antiretroviral treatment to a boosted protease inhibitor and the nucleoside analog lamivudine -- a dual regimen -- is highly effective for people switching from a stable 3-drug regimen, researchers reported this week at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow).
HIV Glasgow: Dolutegravir and Central Nervous System Side-Effects -- Abacavir, Older Age Increase the Risk
- Details
- Category: Approved HIV Drugs
- Created on Friday, 28 October 2016 00:00
Insomnia, dizziness, headache, and other central nervous system (CNS) side effects are occurring more frequently with everyday use of dolutegravir than clinical trials had suggested, and are most likely to occur among women, people over age 60, and people starting abacavir at the same time, a German research group reported at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) this week.
HIV Glasgow: Darunavir/Ritonavir + Lamivudine Matches Triple-Drug HIV Therapy
- Details
- Category: Approved HIV Drugs
- Created on Monday, 07 November 2016 00:00
Simplifying antiretroviral therapy to a 2-drug combination of lamivudine plus the protease inhibitor darunavir (Prezista) boosted by ritonavir is just as effective as a 3-drug regimen in people with suppressed viral load, Spanish investigators reported at the International Congress on Drug Therapy in HIV infection (HIV Glasgow) last month in Glasgow.
HIV Glasgow: Long-Acting HIV Fusion Inhibitor Albuvirtide Regimen Matches Standard Therapy
- Details
- Category: Experimental HIV Drugs
- Created on Monday, 07 November 2016 00:00
A new fusion inhibitor, albuvirtide, under development in China, combined with a boosted protease inhibitor, proved just as effective as a triple regimen of lopinavir/ritonavir plus 2 NRTIs for treatment-experienced HIV patients, according to a report at the International Congress on Drug Therapy in HIV Infection last month in Glasgow.
More Articles...
- HIV Glasgow: Tests of Online PrEP Purchases Find No Fakes and Adequate Drug Levels
- HIV Glasgow: French Study Reveals Growing Complexity of Medical Needs as People with HIV Age
- HIV Glasgow: HIV Treatment Benefits Outweigh Clinical Impact of Lipodystrophy
- HIV Glasgow: New $90-$90-$90 Target Needed for Global Viral Hepatitis, HIV, and TB Treatment
- HIV Glasgow: Generic Hepatitis C Drugs Purchased Online Produce High Cure Rates
Web Design and Development by